Results 201 to 210 of about 20,261,647 (304)

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian, Pedram Asadi Sarabi, Abbas Piryaei, Massoud Vosough   +3 more
wiley   +1 more source

Potential Impact of Frequent Testing for Hepatitis C Virus Among People Who Inject Drugs Toward Hepatitis C Elimination in the United States. [PDF]

Clin Infect Dis
Zhu L, Furukawa NW, Thompson WW, Reitsma MB, Randall LM, Asher AK, Valverde E, Linas BP, Salomon JA.   +8 more
europepmc   +1 more source

Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

BMEMat, EarlyView.
LSPR biosensing enables rapid, sensitive, and low‐sample‐volume detection of biomarkers, with broad applications in diagnosing cancer, infectious, and chronic diseases. Advances in nanostructure design, micro/nanofabrication, and microfluidic integration have expanded the potential of LSPR sensors in biomedical diagnostics.
Zhaoxin Geng, Yunfei Sha, Jiongyan Yang, Hongru Yang, Xiao Liang   +4 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

[Screening of Hepatitis C virus in blood donors over 11 years]. [PDF]

Rev Med Inst Mex Seguro Soc
Rodríguez-Rivera JL, Daniel-Cravioto A, Benítez-Arvizu G.   +2 more
europepmc   +1 more source

Multiscale Modeling of an 8‐Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection

Clinical Pharmacology &Therapeutics, EarlyView.
Bemnifosbuvir (BEM) and ruzasvir (RZR) are pan‐genotypic HCV polymerase (NS5B) and NS5A inhibitors, respectively. In a single‐arm study (NCT05904470), 215 treatment‐naïve, adherent participants with chronic HCV (with or without cirrhosis) received BEM 550 mg QD plus RZR 180 mg QD for 8 weeks.
Carolin Zitzmann, Ruy M. Ribeiro, Aurelien Marc, Xiao‐Jian Zhou, Alan S. Perelson   +4 more
wiley   +1 more source

A Practical Guide to Implementing Real‐World Evidence as Primary Basis for Approval and Label Expansion

Clinical Pharmacology &Therapeutics, EarlyView.
In June 2026, the FDA issued a revised draft guidance describing the circumstances in which one adequate and well‐controlled clinical investigation plus confirmatory evidence may satisfy the statutory substantial evidence standard for establishing efficacy and safety. Confirmatory evidence includes real‐world evidence (RWE).
Tracy J. Mayne, Maurice A. Brookhart, Nancy A. Dreyer   +2 more
wiley   +1 more source

A practical difference from the normal approach to evaluate natural killer (NK) cells and NK cell neoplasms by flow cytometry

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Natural killer (NK) cell neoplasms span indolent to highly aggressive entities, and flow cytometric immunophenotyping is central to their detection and classification. However, distinguishing reactive from neoplastic NK cell expansions can be challenging because NK cells lack somatically recombined antigen receptors, and reactive states may ...
Aaron J. Wilk, Afshin Shameli, Erik Ames, Jonathan R. Fromm, Bartosz Grzywacz, Min Shi, Sindhu Cherian, Jean Oak   +7 more
wiley   +1 more source

High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C. [PDF]

J Hum Immun
Taniguchi M, Tao C, Asano T, Tsumura M, Ko K, Kumada H, Utsumi T, Noma K, Sakura F, Ashihara K, Tamaura M, Mizoguchi Y, Ohara O, Bogunovic D, Bastard P, Casanova JL, Tanaka J, Tsuge M, Chayama K, Oka S, Okada S.   +20 more
europepmc   +1 more source